top of page
Review Article

      Abstract    

        

HOME

PLATELETS IN INFLAMMATORY DISEASES: MEDIATORS OF CLOTTING AND IMMUNE RESPONSES

​

Mohammed Zaid, B Bharathi, Deepa C. Philip

​

ABSTRACT: Excessive and uncontrolled inflammation, coupled with thrombosis, are defining features of immune-mediated inflammatory disorders (IMIDs), contributing to organ damage, increased morbidity, and mortality. While platelets are primarily known for their role in clot formation, emerging research highlights their significant influence on inflammation and immune responses. Platelets engage with white blood cells and accumulate at injury sites, releasing cytokines and chemokines that attract neutrophils and monocytes, thereby amplifying the inflammatory response. In IMID patients, platelets are often activated by disease-specific triggers, with their activation levels correlating closely with disease activity. Beyond clotting, platelets exhibit immune cell-like behavior by engulfing pathogens, contributing to innate immunity. They also play a pivotal role in abnormal tissue healing and injury. Additionally, platelet-derived extracellular vesicles, laden with bioactive molecules, exacerbate inflammation, modulate immune responses, and promote thrombosis, thereby influencing disease progression. In autoimmune diseases, platelets not only support clotting and inflammation but also intensify autoimmunity by activating immune cells and perpetuating inflammatory feedback loops. Research into therapies targeting platelet activation and platelet-immune cell interactions presents promising strategies for managing IMIDs and reducing associated organ damage.

​

KEYWORDS: Intermediated seditious conditions (IMIDs), Platelets, Immune system

​

REFERENCES:​​

  1. [1]. Nathalie conrad, Geert verserke, Geet molenserghs, Laura goatschalechy Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022; 400 Sep 3; 10354:  733–743. 

  2. [2]. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity. 2003; 19:9-19.

  3. [3]. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014: 123,20: 2759-2767

  4. [4]. Marc Scherlinger, Christophe Richez, George c Tsokos, Eric Boilard, Patrick Blanco the role of platelets in immune-mediated inflammatory diseases. Frontiers in Immunology. 2018; 99,11:4021-4029

  5. [5]. Ozge sonmez, Mehmet sonmez Role of platelets in immune system and inflammation. Journal of Immunology Research. 2015; 2,6:311–314

  6. [6]. Youssefian T, Drouin A, Massé JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood. 2002; 99:4021-4029.

  7. [7]. Deyan Luo, Frank Szaba, Lawrences W Kummer, Edward F Plow. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defence against the gram-negative bacterium Yersinia enterocolitica. J. Immunol. 2011; 187: 1866–1876.

  8. [8]. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. Int J Lab Hematol.2013; 35:254-261. 

  9. [9]. Kuwana, M., Kaburaki, J., Okazaki, Y., Miyazaki, H. & Ikeda, Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology 2006; 45: 851–854.

  10. [10]. L.Czirják, Molnar,Csipo, M Szabolcs, A Mihaly.  Anti-platelet antibodies against gpIIb/IIIa in systemic sclerosis. Clin. Exp. Rheumatol.1994; 3: 527–529.

  11. [11]. Boilard, E. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010; 327: 580–583.

  12. [12]. Bai, M. Mean platelet volume could reflect disease activity of adult patients with systemic lupus erythematosus. Clin. Lab. 2016; 62, 1317–1322.

  13. [13]. Khodashahi, M., Saadati, N., Rezaieyazdi, Z., Sahebari, M. & Saremi, Z. Evaluation of mean platelet volume in patients with rheumatoid arthritis and its relation with severity of disease. Rheumatol. Res. 2019; 4, 121–126.

  14. [14]. Pamuk, G. E. Increased circulating platelet–leucocyte complexes in patients with primary Raynaudʼs phenomenon and Raynaudʼs phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul. Fibrinolysis. 2007; 18: 297–302.

  15. [15]. Coenen, D. M., Mastenbroek, T. G. & Cosemans, J. M. E. M. Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 2017 ;130:  2819–2828.

  16. [16]. Kao, K., Cook, D. & Scornik, J. Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody. Blood 1986; 68, 627–632.

  17. [17]. Nhek, S. Activated platelets induce endothelial cell activation via an interleukin-1β pathway in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 2017; 37, 707–716.

  18. [18]. Scherlinger, M.Patrick Blanco. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci. Transl. Med; 2021; 13, 94. 

  19. [19].  Provan, D. & Semple, J. W. Recent advances in the mechanisms and treatment of immune thrombocytopenia. E Bio Medicine2022; 76, 103820.

  20. [20]. Kocovski, P. et al. Platelet depletion is effective in ameliorating anxiety-like behavior and reducing the pro-inflammatory environment in the hippocampus in murine experimental autoimmune encephalomyelitis. J. Clin. Med 2021; 8, 162.

  21. [21]. Kronbichler, A. & Mayer, G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013; 11: 95.

  22. [22]. Binita Shah, Nicole Allen, Michael Pillinger, stuart Katz. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation 2016; 39: 182–189.

  23. [23]. Sung P.S., Huang T.F., Hsieh S.L. Extracellular vesicles from CLEC2-activated platelets enhance dengue virus-induced lethality via CLEC5A/TLR2. Nat. Commun. 2019;10: 2402.

  24. [24]. Delierneux C., Donis N., Servais L., Wéra O., Lecut C., Vandereyken M., Musumeci L., Rahmouni S., Schneider J., Eble J.A. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides. J. Thromb. Haemost. 2017; 15:983–997.

  25. [25]. Simon A.Y., Sutherland M.R., Pryzdial E.L. Dengue virus binding and replication by platelets. Blood. 2015; 126:378–385.

  26. [26]. Assinger A., Laky M., Schabbauer G., Hirschl A.M., Buchberger E., Binder B.R., Volf I. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J. Thromb. Haemost. 2011; 9:799–809. 

 To cite this article:

 Zaid M, Bharathi B, Philip BC. Platelets in inflammatory diseases: mediators of clotting and immune responses.  Int. J. Med. Lab. Res. 2025;10,1:1-7. http://doi.org/10.35503/IJMLR.2025.10101

bottom of page